The FDA approval of Kymriah™ has shifted the paradigm for pediatric cancer treatment — and at Children's Hospital of Philadelphia, more cell therapies are on the horizon.

Researchers have found key differences among the most common types of pediatric brain tumors that may lead to more effective therapy.

By identifying common gene variants that raise the risk of an aggressive form of the childhood cancer neuroblastoma, researchers may assist diagnostic efforts.

This is a game changer for the treatment of pediatric patients battling leukemia and a pivotal milestone in this new era of cellular therapies that treat cancer with a patient’s own immune system.

Newly created videos allow families to see the facilities’ interiors and better understand what will happen during an outpatient visit before their scheduled appointment.

Since its inception in October 2016, the workshop has created recommendations for the 50 most common syndromes that predispose children to cancer and produced 16 position papers.

Thanks to a recent initiative at CHOP, patients newly diagnosed with B-cell and T-cell ALL, and lymphoblastic lymphoma, now go home on average 9 days after diagnosis — that's 3 weeks sooner than previous stays.

Five years after her T-cell therapy for ALL, Emily remains cancer-free. CHOP has since treated more than 170 patients in clinical trials that have seen a 93% remission rate.

The experimental, personalized cell therapy that amps up the patient's own immune system has passed a critical milestone in the path to full FDA approval.

A DNA-cutting enzyme that regulates gene structure has a broad role in causing certain cancers. This discovery may eventually lead to more precise treatments.